Record growth at The Wasdell Group7 Nov 2018
Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.
The Wasdell Group, an outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue growth in the last 24 months, following an increase in demand for its clinical trial, manufacturing and packing services.
Wasdell enter the final quarter of 2018 with a revenue of £41M, a considerable increase compared with £28M in 2016. This record growth has allowed the company to expand its clinical development, manufacturing and packaging capabilities, as well as invest in an on-site laboratory and build its first site outside of the UK.
Martin Tedham, CEO at The Wasdell Group said: “Our strong growth can be largely attributed to the number of pre-clinical development projects that we have recently been awarded, as well as our ongoing work in our manufacturing division.
“It is clear we are becoming more established across the pharmaceutical sector for our efficient service and ability to support customers with end-to-end supply needs. We are not only receiving an influx of new business, but more of our customers are also recognising the advantages of outsourcing more of their operations to Wasdell.”
Following the completion of building work on its new site in Dundalk, Ireland – due to finish in spring 2019 – the company will add 300 new members of staff to its team talking the total number of employees to 1000.
Martin continued: “Despite Brexit looming, our EU & UK business has increased by almost 30% in the last 12 months. We have also strengthened our partnerships with a number of US customers as a result of futureproofing our position as a reliable stepping stone into European market.
“Looking back to 2009 we were turning over just under £2m so to hit our £40M target fills me with a huge amount of pride and gratitude to our customers and our employees. I believe the customer-centric approach Wasdell has always taken, whether it be in delivery of our work or in the investments we have made, has played a huge part in our success today. I can’t wait to see what the future holds.”
Wasdell has ongoing plans to continue investing in its manufacturing and distribution facilities across the UK, especially at its Swindon site which is set to expand in 2019. This next round of investment will cater for the company’s forecasted growth which is estimated to increase by a further 25% by 2020.
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Lilly to bag Loxo Oncology for $8 billion
8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.Read more
Catalent to double its commercial biomanufacturing capacity
7 Jan 2019
The $200-million expansion will support customers’ development programs and commercial launches.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
Cambrex completes acquisition of Avista Pharma Solutions
2 Jan 2019
Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.Read more
Novartis offers to acquire CellforCure
1 Jan 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.Read more
BMS receives offer from Taisho to purchase UPSA
30 Dec 2018
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.Read more
Recipharm to potentially end operations in Ashton-under-Lyne facility
24 Dec 2018
The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation